Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT06314230
Recruiting Observational

Australian Genomics Of Chronic Allograft Dysfunction Study

NCT06314230 · tracked via the Priya Life Science Australia tracker
Sponsor
Western Sydney Local Health District
Phase
Observational
Started
2012-04-26
Last updated
2025-07-17

Condition(s) studied

Kidney Transplant RejectionKidney Transplant; Complications

Study summary

The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Living or deceased donor kidney transplant candidate. * Biological sex: any * Ages: 18-75 years. * Subject must be able to understand and provide informed consent. * Deceased donor individuals where Research Consent has been obtained from the person consenting to organ donation at the time of organ retrieval. * Identifiable living donors who have received informed consent and have consented to participate in the project. Exclusion Criteria: * Presensitization in living donor recipients prior to transplantation, as determined by site-specific standards, OR positive cross match according to site specific technique in cadaveric donor recipients. * Recipients of multiple organ transplants, with the exception of kidney/pancreas transplants. * Inability or unwillingness of a participant to give written informed consent or comply with study protocol * High risk populations including pregnant women, children less than 18 years and prisoners will not be included in the study. * Non English speaking potential participants who do not understand the requirements of the study will not be included.

Primary outcome measure(s)

  • Graft failure — Time Frame: At biopsy or during study follow up after biopsy (expected average 60-months)
    Failure of the kidney transplant, resulting in death or return to dialysis
  • Allograft rejection — At biopsy or during study follow up after biopsy (expected average 12-months)
    Any rejection (acute or chronic, borderline, T-cell, antibody or mixed rejection) in the kidney transplant
  • Gene profile — At biopsy - based on collected tissue sample
    Gene expression or variant profiles of participants

Trial sites (2)

FacilityCityRegionStatus
Westmead Hospital Westmead New South Wales Recruiting
Westmead Institute for Medical Research Westmead New South Wales Recruiting

More Western Sydney Local Health District trials in Australia

The Australian Colonic Large Sessile Lesion Endoscopic Resection Study Recruiting
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers Recruiting
GENomic Predictors in A Multi-Ethnic Population With Kidney Disease Study Enrolling by invitation
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD) Recruiting
Cold Snare Endoscopic Mucosal Resection (EMR) vs Cold EMR With Margin Snare Tip Soft Coagulation (STSC) Recruiting

Other trials for the same condition

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation Recruiting
Trifecta-Kidney cfDNA-MMDx Study Recruiting
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06314230 on ClinicalTrials.gov ↗ ← All trials in Australia